Lexeo Therapeutics

Historical price data

Lexeo Therapeutics is pioneering gene therapies for diseases with high unmet medical need, leveraging its expertise in AAV vector design and delivery. The company's strategy focuses on validated biological targets and established gene therapy constructs to potentially accelerate development and reduce risk. Key milestones include advancing its lead cardiovascular candidate, LX2006 for Friedreich's ataxia cardiomyopathy, and its CNS candidate, LX1001 for APOE4-associated Alzheimer's disease, through clinical trials. With a management team experienced in gene therapy development and a public listing providing capital access, Lexeo is positioned to advance its pipeline toward potential regulatory approvals.

Adeno-associated virus (AAV)-based gene therapy platform utilizing specific serotypes for targeted delivery to cardiac tissue and the central nervous system.

2 drugs in pipeline

Total raised: $185M

Lexeo faces limited direct competition in its specific gene therapy approaches for FA cardiomyopathy and APOE4-Alzheimer's, but operates in broader competitive markets for these diseases. In FA, it competes with Larimar Therapeutics' protein replacement and Biogen's approved small molecule. In Alzheimer's, it faces dominant anti-amyloid antibodies from Eisai/Biogen and Lilly. Its differentiation is its targeted genetic mechanism and one-time treatment potential.